PL1668027T3 - Cykliczne peptydy działające jako antagoniści Urotensyny-II - Google Patents

Cykliczne peptydy działające jako antagoniści Urotensyny-II

Info

Publication number
PL1668027T3
PL1668027T3 PL04787113T PL04787113T PL1668027T3 PL 1668027 T3 PL1668027 T3 PL 1668027T3 PL 04787113 T PL04787113 T PL 04787113T PL 04787113 T PL04787113 T PL 04787113T PL 1668027 T3 PL1668027 T3 PL 1668027T3
Authority
PL
Poland
Prior art keywords
urotensin
antagonists
cyclic peptides
peptides acting
acting
Prior art date
Application number
PL04787113T
Other languages
English (en)
Inventor
Ettore Novellino
Paolo Grieco
Paolo Rovero
Original Assignee
Ettore Novellino
Paolo Grieco
Paolo Rovero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ettore Novellino, Paolo Grieco, Paolo Rovero filed Critical Ettore Novellino
Publication of PL1668027T3 publication Critical patent/PL1668027T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL04787113T 2003-09-11 2004-09-09 Cykliczne peptydy działające jako antagoniści Urotensyny-II PL1668027T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000238A ITFI20030238A1 (it) 2003-09-11 2003-09-11 Peptidi ciclici antagonisti dell'urotensina-ii
PCT/EP2004/052101 WO2005023845A2 (en) 2003-09-11 2004-09-09 Cyclic peptides acting as urotensin-ii antagonists
EP04787113A EP1668027B1 (en) 2003-09-11 2004-09-09 Cyclic peptides acting as urotensin-ii antagonists

Publications (1)

Publication Number Publication Date
PL1668027T3 true PL1668027T3 (pl) 2010-10-29

Family

ID=34260004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04787113T PL1668027T3 (pl) 2003-09-11 2004-09-09 Cykliczne peptydy działające jako antagoniści Urotensyny-II

Country Status (10)

Country Link
EP (1) EP1668027B1 (pl)
AT (1) ATE468352T1 (pl)
DE (1) DE602004027272D1 (pl)
DK (1) DK1668027T3 (pl)
ES (1) ES2346223T3 (pl)
IT (1) ITFI20030238A1 (pl)
PL (1) PL1668027T3 (pl)
PT (1) PT1668027E (pl)
SI (1) SI1668027T1 (pl)
WO (1) WO2005023845A2 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037856A1 (en) 1999-11-29 2001-05-31 Smithkline Beecham Corporation Urotensin-ii cyclic analogs
EP1233774A4 (en) 1999-11-29 2004-06-16 Smithkline Beecham Corp UROTENSIN II ANALOGS

Also Published As

Publication number Publication date
WO2005023845A2 (en) 2005-03-17
SI1668027T1 (sl) 2010-09-30
ATE468352T1 (de) 2010-06-15
ES2346223T3 (es) 2010-10-13
EP1668027B1 (en) 2010-05-19
WO2005023845A3 (en) 2005-05-26
PT1668027E (pt) 2010-10-08
EP1668027A2 (en) 2006-06-14
ITFI20030238A1 (it) 2005-03-12
DE602004027272D1 (de) 2010-07-01
DK1668027T3 (da) 2010-08-23

Similar Documents

Publication Publication Date Title
ZA200701656B (en) Humanized anti-cment antagonists
MA29088B1 (fr) Composes d'indazole-carboxamide.
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY142044A (en) Endoparasiticidal compositions for topical application
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ATE398630T1 (de) Zyklische conotoxin-peptide
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
WO2004047771A3 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
TW200611695A (en) Pyrrolopyridine derivatives
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
TW200531686A (en) Pharmaceutical compositions
WO2001005811A3 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
UA86091C2 (ru) Непептидные антагонисты брадикинина и их фармацевтическая композиция
MY130373A (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
IL188848A (en) A transient receptor antagonist (TRPVI) i, a pharmaceutical preparation containing it for the treatment of related diseases and conditions.
SI1668027T1 (sl) Ciklični peptidi delujoči kot antagonisti urotenzina ii
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling